CORRELATION BETWEEN CHANGES IN CHOROIDAL THICKNESS AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER AFLIBERCEPT INTRAVITREAL INJECTION | ||||
| ALEXMED ePosters | ||||
| Article 1, Volume 7, Issue 1, January 2025, Page 55-56 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2025.367344.2113 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Samir Mohamed Elbaha1; Amr Ahmed Said2; Abubakr Mahmoud Abubakr Elwani  1
| ||||
| 1Department of Ophthalmology, Faculty of Medicine, University of Alexandria. | ||||
| 2Ophthalmology department Alexandria University | ||||
| Abstract | ||||
| Epidemiology Age-related macular degeneration is the most common cause of permanent visual loss around the world in people over the age of 65 years in developed countries, the disease forms about 9% of blindness cases. The number is expected to reach about 300 million by 2040. Risk factors for AMD Other than age, white race, female gender, arterial hypertension, hypercholesterolemia, cardiovascular disease, obesity, positive family history, smoking, high levels of C-reactive protein and other inflammatory markers, hyperopia, and light-colored iris are risk factors for developing AMD. Smoking is the most important modifiable risk factor. Types of AMD 1) Dry AMD Drusen, pigmentary changes in the retina, RPE atrophy or geographic atrophy may be present. 2) Wet AMD Signs of wet type include RPE detachment, subretinal fluid, subretinal hemorrhage and choroidal neovascularization. Types of CNV 1) Type 1 (occult or subRPE) 2) Type 2 (classic or subretinal) 3) Type 3 (retinal angiomatous proliferation RAP) Treatment Life style modification, photodynamic therapy and anti-VEGF agents are treatment modalities. | ||||
| Keywords | ||||
| CHOROIDAL THICKNESS; VISUAL ACUITY; AGE-RELATED MACULAR DEGENERATION | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 59 |
||||
